EP Patent

EP4724462A1 — Stabilized flavivirus vaccines

Assigned to ModernaTx Inc · Expires 2026-04-15 · 0y expired

What this patent protects

Provided herein are engineered flavivirus heterotetrameric proteins (.e.g., Envelope and/or Membrane proteins) comprising at least one stabilizing amino acid substitution. The engineered flavivirus proteins form a stabilized heterotetramer structure. Messenger ribonucleic acid va…

USPTO Abstract

Provided herein are engineered flavivirus heterotetrameric proteins (.e.g., Envelope and/or Membrane proteins) comprising at least one stabilizing amino acid substitution. The engineered flavivirus proteins form a stabilized heterotetramer structure. Messenger ribonucleic acid vaccines encoding the engineered flavivirus proteins are also provided. The disclosure also provides methods of eliciting an immune response and/or neutralizing antibodies to flavivirus in a subject.

Drugs covered by this patent

Patent Metadata

Patent number
EP4724462A1
Jurisdiction
EP
Classification
—
Expires
2026-04-15
Drug substance claim
No
Drug product claim
No
Assignee
ModernaTx Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.